Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours

Clinical and Translational Oncology

Volumn 16, Issue 7, 2014, Pages 593-598

  Li, C ^a   Sun, B Q ^a   Gai, X D ^a  

^a BEIHUA UNIVERSITY   (China)

Author keywords

Chinese herbal medicines; Compound; Multidrug resistance; P glycoprotein; Reversal agent

Indexed keywords

ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PHYSIOLOGY; PHYTOTHERAPY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; HUMANS; P-GLYCOPROTEIN; PHYTOTHERAPY;

EID: 84905680027     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1169-7     Document Type: Review

References (71)

1. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006;580:998-1009. (Pubitemid 43185280)
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-62.
3. Solazzo M, Fantappiè O, Lasagna N, Sassoli C, Nosi D, Mazzanti R. P-gp localization in mitochondria and its functional characterization in multiple drugresistant cell lines. Exp Cell Res. 2006;312:4070-8. (Pubitemid 44834517)
4. Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res. 2007;55:1-15. (Pubitemid 46108588)
5. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003;88:1963-70. (Pubitemid 36829675)
6. Balimane PV, Marino A, Chong S. P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate? AAPS J. 2008;10:577-86.
7. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATPdependent transporters. Nat Rev Cancer. 2002;2:48-58. (Pubitemid 37328807)
8. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323:1718-22.
9. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005;5:30.
10. Sekiya N, Hikiami H, Yokoyama K, Kouta K, Sakakibara I, Shimada Y, et al. Inhibitory effects of Stephania tetrandra S. Moore on free radical-induced lysis of rat red blood cells. Biol Pharm Bull. 2005;28:667-70. (Pubitemid 40879935)
11. He L, Liu GQ. Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol Sin. 2002;23:591-6. (Pubitemid 34733319)
12. Sun AX, Ye ZG, Li CY, Xue BY, Li LF, Cao XF, et al. Synergistic anticancer effects of tetrandrine combined with doxorubicin or vincristine in vitro. Zhongguo Yao Li Xue Bao. 1999;20:69-73 (in Chinese).
13. Lu XJ, Xu WL, Luo WJ, Wang FC, Chen QY. Effect of tetrandrine on the doxorubicin-induced expression of mdr1 gene in K562 cells. Zhonghua Xue Ye Xue Za Zhi. 2008;29:468-71 (in Chinese).
14. Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer. 2002;38:418-26. (Pubitemid 34121971)
15. Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, et al. Characterization of tetrandrin, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol. 2004;53:349-56. (Pubitemid 38392360)
16. Wang JH, Ye ZG, Sun AX, Xue BY, Liang AH, Li CY, et al. Reversal of antiapoptotic action by tetrandrine in human breast carcinoma multidrug-resistant MCF-7 cells. Zhongguo Zhong Yao Za Zhi. 2002;27:46-50 (in Chinese).
17. Dai CL, Xiong HY, Tang LF, Zhang X, Liang YJ, Zeng MS, et al. Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol. 2007;60:741-50. (Pubitemid 47247285)
18. Xu WL, Shen HL, Ao ZF, Chen BA, Xia W, Gao F, et al. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res. 2006;30:407-13. (Pubitemid 43254962)
19. Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, et al. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013;341:139-49.
20. Liu A, Chen H, Wei W, Ye S, Liao W, Gong J, et al. Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol Rep. 2011;26:81-9.
21. Sun Y. Chemosensitization by emodin, a plant-derived anti-cancer agent: mechanism of action. Cancer Biol Ther. 2008;7:476-8.
22. Dorsey JF, Kao GD. Aloe(-emodin) for cancer? More than just a comforting salve. Cancer Biol Ther. 2007;6:89-90. (Pubitemid 46294183)
23. Liu DL, Bu H, Li H, Chen H, Guo HC, Wang ZH, et al. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro. Int J Oncol. 2012;40:1049-57.
24. Li J, Liu P, Mao H, Wanga A, Zhang X. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep. 2009;21:1605-10.
25. Huang XZ, Wang J, Huang C, Chen YY, Shi GY, Hu QS, et al. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther. 2008;7:468-75. (Pubitemid 351847069)
26. Zhang W, Chen H, Liu DL, Li H, Luo J, Zhang JH, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013;42:1189-96.
27. Shinkai K, Akedo H, Mukai M, Imamura F, Isoai A, Kobayashi M, et al. Inhibition of in vitro tumor cell invasion by ginsenoside Rg3. Jpn J Cancer Res. 1996;87:357-62. (Pubitemid 26147848)
28. Mochizuki M, Yoo YC, Matsuzawa K, Sato K, Saiki I, Tono-oka S, et al. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. Biol Pharm Bull. 1995;18:1197-202.
29. Kim ND, Kim EM, Kang KW, Cho MK, Choi SY, Kim SG. Ginsenoside Rg3 inhibits phenylephrine-induced vascular contraction through induction of nitric oxide synthase. Br J Pharmacol. 2003;140:661-70. (Pubitemid 37386430)
30. Wei X, Chen J, Su F, Su X, Hu T, Hu S. Stereospecificity of ginsenoside Rg3 in promotion of the immune response to ovalbumin in mice. Int Immunol. 2012;24:465-71.
31. Kim SW, Kwon HY, Chi DW, Shim JH, Park JD, Lee YH, et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem Pharmacol. 2003;65:75-82.
32. Kwon HY, Kim EH, Kim SW, Kim SN, Park JD, Rhee DK. Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation. Arch Pharm Res. 2008;31:171-7.
33. Lu P, Su W, Miao ZH, Niu HR, Liu J, Hua QL. Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med. 2008;14:33-6. (Pubitemid 351488147)
34. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985;228:1049-55. (Pubitemid 15227365)
35. Hsu E. Reflections on the 'discovery' of the antimalarial qinghao. Br J Clin Pharmacol. 2006;61:666-70. (Pubitemid 43794791)
36. Yu HP, Cui L, Pan YJ. Reversal of drug resistance in multidrug-resistant MCF-7/ADR cells of breast cancer by artemisinin. Hua Zhong Ke Ji Da Xue Xue Bao Yi Xue Ban. 2011;40:91-4 (in Chinese).
37. Reungpatthanaphong P, Mankhetkorn S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull. 2002;25:1555-61. (Pubitemid 39663669)
38. Liu L, Zuo LF, Guo JW. Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line. Oncol Lett. 2013;6:1475-81.
39. Huang RL, Chen CC, Huang YL, Hsieh DJ, Hu CP, Chen CF, et al. Osthole increases glycosylation of hepatitis B surface antigen and suppresses the secretion of hepatitis B virus in vitro. Hepatology. 1996;24:508-15.
40. Liu JH, Zschocke S, Reininger E, Bauer R. Inhibitory effects of Angelica pubescens f. biserrata on 5-lipoxygenase and cyclooxygenase. Planta Med. 1998;64:525-9. (Pubitemid 28383885)
41. Matsuda H, Tomohiro N, Ido Y, Kubo M. Anti-allergic effects of cnidii monnieri fructus (dried fruits of Cnidium monnieri) and its major component, osthol. Biol Pharm Bull. 2002;25:809-12. (Pubitemid 40036723)
42. Zhang QL, Zhao JH, Bi JJ, Cao JR, Song J, Wu ZZ. Three coumarins from seed of Cnidium monnieri and their multidrug resistance reversal effects. Zhong Chao Yao. 2003;34:104-6 (in Chinese).
43. Wang XH, Zhang SJ, Guo X, Sun ML, Li QP, Liu HY. Reversal effect and mechanism of osthole on the multidrug-resistance of human bladder cancer cells T24/ADM. Zhongguo Dang Dai Yi Yao. 2012;19:7-9 (in Chinese).
44. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol. 2003;475:19-27.
45. Teng CM, Chen CC, Ko FN, Lee LG, Huang TF, Chen YP, et al. Two antiplatelet agents from Magnolia officinalis. Thromb Res. 1988;50:757-65.
46. Liou KT, Lin SM, Huang SS, Chih CL, Tsai SK. Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Med. 2003;69:130-4.
47. Woodbury A, Yu SP, Wei L, García P. Neuro-modulating effects of honokiol: a review. Front Neurol. 2013;4:130.
48. Tian W, Deng Y, Li L, He H, Sun J, Xu D. Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death. Int J Oncol. 2013;42:721-32.
49. Xu D, Lu Q, Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett. 2006;243:274-80. (Pubitemid 44485849)
50. Xue F, Cheng ZY, Liang WT, Chen H, Wang SY, Yao L. Resistance reverse effects of honokiol on multidrug resistance of U937/ADR cell line. Shanhai Jiao Tong Da Xue Xue Bao Yi Xue Ban. 2009;29:1035-9 (in Chinese).
51. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and-independent apoptosis. Blood. 2005;106:1794-800. (Pubitemid 41208596)
52. Bailey HH, Mukhtar H. Green tea polyphenols and cancer chemoprevention of genitourinary cancer. Am Soc Clin Oncol Educ Book. 2013;2013:92-6.
53. Cai YJ, Ma LP, Hou LF, Zhou B, Yang L, Liu ZL. Antioxidant effects of green tea polyphenols on free radical initiated peroxidation of rat liver microsomes. Chem Phys Lipids. 2002;120:109-17. (Pubitemid 35333404)
54. Chen D, Wan SB, Yang H, Yuan J, Chan TH, Dou QP. EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem. 2011;53:155-77.
55. Xuan W, Wang S, Han C, Chen J. Study on the inhibition of tea pigments on the adhesion between monocyte and endothelial cells. Wei Sheng Yan Jiu. 2001;30:44-6 (in Chinese).
56. Zhu A, Wang X, Guo Z. Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent). Nucl Med Biol. 2001;28:735-40. (Pubitemid 32772878)
57. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta. 2002;1542:149-59.
58. Mei Y, Wei D, Liu J. Reversal of cancer multidrug resistance by tea polyphenol in KB cells. J Chemother. 2003;15:260-5. (Pubitemid 36819315)
59. Mei Y, Qian F, Wei D, Liu J. Reversal of cancer multidrug resistance by green tea polyphenols. J Pharm Pharmacol. 2004;56:1307-14. (Pubitemid 39369002)
60. Mei Y, Wei D, Liu J. Reversal of multidrug resistance in KB cells with tea polyphenol antioxidant capacity. Cancer Biol Ther. 2005;4:468-73. (Pubitemid 41351267)
61. Zhang Q, Wei D, Liu J. In vivo reversal of doxorubicin resistance by (-)- epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett. 2004;208:179-86. (Pubitemid 38624159)
62. Jing WG, Zhang J, Zhang LY, Wang DZ, Wang YS, Liu A. Application of a rapid and efficient quantitative analysis method for traditional Chinese medicines: the case study of quality assessment of Salvia miltiorrhiza Bunge. Molecules. 2013;18:6919-35.
63. Liu CJ, Liu JG, Yu TC. Tanshinone microemulsion reverses multidrug resistance of tumor. Zhongguo Lin Chuang Kang Fu. 2006;10:181-4 (in Chinese).
64. Jiang YR, Chen KJ. Pharmacological roles of ligustrazine in cardio-/cerebrovascular systems and its progress in researches of clinical application. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013;33:707-11 (in Chinese).
65. Xie X, Yang Y, Gao QB. Effect of TMP on multidrug resistance reversal and P-gp expression in human breast cancer cell line MCF-7/ADM. Da Lian Da Xue Xue Bao. 2006;27:76-8 (in Chinese).
66. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem. 2004;4:873-9. (Pubitemid 39200074)
67. Sadava D, Still DW, Mudry RR, Kane SE. Effect of Ganoderma on drugsensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett. 2009;277:182-9.
68. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275-92. (Pubitemid 40227997)
69. Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003;2:1195-205.
70. Xie L, Zhai X, Ren L, Meng H, Liu C, Zhu W, et al. Design, synthesis and antitumor activity of novel artemisinin derivatives using hybrid approach. Chem Pharm Bull (Tokyo). 2011;59:984-90.
71. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, et al. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs. 2010;21:423-32.